دورية أكاديمية
أعرض في EDS

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

التفاصيل البيبلوغرافية
العنوان: Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
المؤلفون: Mercer LK; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK., Galloway JB; Department of Rheumatology, King's College London, London, UK., Lunt M; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK., Davies R; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK., Low AL; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK., Dixon WG; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.; NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, Manchester, UK., Watson KD; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK., Symmons DP; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.; NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, Manchester, UK., Hyrich KL; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.; NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, Manchester, UK.
مؤلفون مشاركون: BSRBR Control Centre Consortium
المصدر: Annals of the rheumatic diseases [Ann Rheum Dis] 2017 Mar; Vol. 76 (3), pp. 497-503. Date of Electronic Publication: 2016 Aug 08.
نوع المنشور: Journal Article; Observational Study
اللغة: English
بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: London : BMJ
Original Publication: London : H.K. Lewis
مواضيع طبية MeSH: Antirheumatic Agents/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , Arthritis, Rheumatoid/*epidemiology , Lymphoma/*epidemiology , Tumor Necrosis Factor-alpha/*antagonists & inhibitors, Adalimumab/therapeutic use ; Adult ; Aged ; Case-Control Studies ; Etanercept/therapeutic use ; Female ; Follow-Up Studies ; Humans ; Incidence ; Infliximab/therapeutic use ; Male ; Middle Aged ; Prospective Studies ; Registries ; Risk Assessment ; United Kingdom/epidemiology
مستخلص: Objectives: Patients with rheumatoid arthritis (RA) are at increased risk of lymphoma compared with the general population. There are concerns that tumour necrosis factor inhibitors (TNFi) may exacerbate this risk. However, since the excess risk of lymphoma in RA is related to the cumulative burden of inflammation, TNFi may conversely reduce the risk of lymphoma by decreasing the burden of inflammation. The aim of this study was to compare the risk of lymphoma in subjects with RA treated with TNFi with those treated with non-biological therapy.
Methods: Subjects diagnosed by a rheumatologist with RA enrolled in the British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR-RA), a prospective cohort study, were followed until first lymphoma, death or until 30 November 2013. Rates of lymphoma in the TNFi and non-biological-treated cohorts were compared using Cox regression.
Results: 11 931 TNFi-treated patients were compared with 3367 biological-naive patients. 84 lymphomas (88 (95% CI 70 to 109) per 100 000 person-years) were reported in the TNFi cohort and 30 lymphomas (154 (95% CI 104 to 220)) in the biological-naive cohort. After adjusting for differences in baseline characteristics, there was no difference in the risk of lymphoma for the TNFi versus the biological-naive group: HR 1.00 (95% CI 0.56 to 1.80). No risk differences were observed for individual TNFi.
Conclusions: In medium-term follow-up, there is no evidence that tumour necrosis factor inhibition influences the risk of lymphoma over the background risk in subjects with RA.
(Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)
التعليقات: Comment in: Ann Rheum Dis. 2017 Feb;76(2):e3. (PMID: 27742658)
Comment in: Ann Rheum Dis. 2017 Feb;76(2):e4. (PMID: 27934677)
References: Lancet. 1999 Dec 4;354(9194):1932-9. (PMID: 10622295)
Arthritis Rheum. 2006 Mar;54(3):692-701. (PMID: 16508929)
Rheumatology (Oxford). 2013 Jan;52(1):91-8. (PMID: 23238979)
Arthritis Rheum. 2007 May;56(5):1433-9. (PMID: 17469100)
Arthritis Rheum. 1995 Jan;38(1):44-8. (PMID: 7818570)
J Rheumatol. 1999 Aug;26(8):1705-14. (PMID: 10451066)
J Chronic Dis. 1978;31(11):691-6. (PMID: 730824)
Ann Rheum Dis. 2013 Jan;72(1):79-82. (PMID: 22945500)
JAMA. 2006 May 17;295(19):2275-85. (PMID: 16705109)
Arthritis Rheum. 2003 Jan;48(1):35-45. (PMID: 12528101)
J Natl Cancer Inst. 2006 Jan 4;98(1):51-60. (PMID: 16391371)
Arthritis Rheum. 2003 Jun;48(6):1543-50. (PMID: 12794821)
Nat Rev Cancer. 2009 May;9(5):361-71. (PMID: 19343034)
Ann Rheum Dis. 2010 Feb;69(2):400-8. (PMID: 19828563)
Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv42-3. (PMID: 16239385)
Arthritis Res Ther. 2008;10(2):R45. (PMID: 18433475)
Arthritis Rheum. 2013 Jan;65(1):48-58. (PMID: 23055441)
Br J Rheumatol. 1986 May;25(2):206-9. (PMID: 3708236)
Lancet. 2004 Feb 28;363(9410):675-81. (PMID: 15001324)
Ann Rheum Dis. 2009 Aug;68(8):1240-6. (PMID: 18647854)
Joint Bone Spine. 2002 Jan;69(1):12-8. (PMID: 11858351)
PLoS One. 2012;7(1):e30275. (PMID: 22272322)
Ann Rheum Dis. 2009 Jul;68(7):1136-45. (PMID: 18753157)
Ann Rheum Dis. 2009 May;68(5):648-53. (PMID: 18467516)
Br J Haematol. 2013 Nov;163(4):465-77. (PMID: 24033296)
JAMA. 2012 Sep 5;308(9):898-908. (PMID: 22948700)
Ann Rheum Dis. 2011 Nov;70(11):1895-904. (PMID: 21885875)
Arthritis Rheum. 2002 Dec;46(12):3151-8. (PMID: 12483718)
معلومات مُعتمدة: 20747 United Kingdom VAC_ Versus Arthritis; G0902272 United Kingdom MRC_ Medical Research Council
فهرسة مساهمة: Investigator: N Maiden; T Price; N Hopkinson; S O'Reilly; L Hordon; I Griffiths; D Porter; R Madhok; A Hassell; RG Cooper; E Choy; D Walsh; PP Emery; S Knight; I Bruce; A Taggart; PD Scott; P Thompson; F McCrae; R Goodfellow; PG Kitas; R Jubb; R Abernethy; S Green; P Sanders; A Coulson; B Harrison; M Bukhari; P Klimiuk
Keywords: Anti-TNF; Epidemiology; Rheumatoid Arthritis
المشرفين على المادة: 0 (Antirheumatic Agents)
0 (Tumor Necrosis Factor-alpha)
B72HH48FLU (Infliximab)
FYS6T7F842 (Adalimumab)
OP401G7OJC (Etanercept)
تواريخ الأحداث: Date Created: 20160810 Date Completed: 20170613 Latest Revision: 20210109
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC5446004
DOI: 10.1136/annrheumdis-2016-209389
PMID: 27502891
قاعدة البيانات: MEDLINE
الوصف
تدمد:1468-2060
DOI:10.1136/annrheumdis-2016-209389